Hospira Launches Generic Cancer Medication
Posted on: Thursday, 28 February 2008, 09:00 CST
Hospira has launched irinotecan hydrochloride injection in the US for patients with colon or rectal cancer whose disease has recurred or progressed following therapy with other treatments.
The medication is a generic version of Pfizer's Camptosar. Hospira's irinotecan product portfolio extends beyond the formulations available from the innovator. In addition to offering the medication in 40mg and 100mg single-dose vials, Hospira is also marketing a 500mg single-dose vial, for additional convenience when preparing and delivering larger doses. The company packages irinotecan in its proprietary Onco-Tain vials for safe handling.
Robert Felicelli, vice president and general manager of Hospira, said: "We are continuing to grow our leading portfolio of generic medications used to treat patients with cancer. By providing irinotecan and other high-quality, lower-cost alternatives to proprietary medications, Hospira is meeting patient needs in this fast-growing therapeutic area."
Source: Datamonitor
Related Articles
- Hospira Unveils Symbiq(TM) Next-Generation Infusion System
- Hospira Announces $2 Billion Agreement to Acquire Mayne Pharma
- Hospira Announces New Contract With HealthTrust to Provide Pain Management Infusion Pumps to Members
- Hospira Introduces Plum A+(R)3 Infusion System With Hospira MedNet(R) Software
- Hospira Wins Approval to Use City Bonds for Expansion in McPherson, Kan.
- Hospira Completes Physiometrix Acquisition
- Physiometrix Announces Receipt of Shareholder Vote for Acquisition By Hospira
- Hospira Ships First Orders of Ceftriaxone Injection
- The Effect of Granisetron on in Vitro Metabolism of Doxorubicin, Irinotecan and Etoposide
User Comments (0)
RSS Feeds